Resource Center

www.lls.org/resourcecenter

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:

donate

November 7, 2013 - Myeloma - Update on Treatment and Side Effects Management

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: November 7, 2013
Time: 1:00 p.m. - 2:30 p.m. ET
Location: Telephone/Web
View: Program Slides
Read: Myeloma Newsletter | Written Transcript
Listen: Presentation | Q&A Session
Access: Virtual Lecture

Topics Covered

  • Goals of myeloma treatment
  • Current and emerging therapies for myeloma, including updates on stem cell transplantation and maintenance therapy
  • Updates on side effects management
  • The importance of patient-provider communications in treatment and side effects management

Speaker

Asher A. Chanan-Khan, MD
Professor of Medicine, Mayo School of Medicine
Chair, Division of Hematology/Oncology
Vice Chair, Research
Chair, Clinical Research Subcommittee
Assistant Director, Center for Individualized Medicine
Department of Medicine
Mayo Clinic
Jacksonville, FL  

Questions Asked by the Myeloma Community

  • What are the benefits and risks of a chemotherapy holiday after 16 months of lenalidomide (Revlimid®) therapy, 12 months of bortezomib (Velcade®) plus Revlimid prior to the Revlimid alone?
  • Could you speak about secondary cancers associated with taking Revlimid?
  • What is the recommendation for the length of time a patient should be on Revlimid, after having melphalan previously?
  • Can you compare the effectiveness of chemotherapy with a transplant? Does one approach lead to a better survival rate or is it patient-dependent?
  • Would taking Revlimid and dexamethasone cause a side effect of short-term memory loss?
  • Where can patients send their bodies for myeloma research when they die?
  • What can be done to reduce skin reaction to the injection site when using Velcade?
  • If immunoglobulins over-produce in myeloma, then why would a patient's immunoglobulins always be very low?
  • How often should a PET or CT scan be done to track the lesions of multiple myeloma?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by grants from Celgene CorporationMillennium: The Takeda Oncology Company and Onyx Pharmaceuticals.

last updated on Thursday, September 11, 2014
btn_sharethis